Treats clinically important hypotension resulting primarily from vasodilation in the…. ANDA 210025, held by Ph Health. Phenylephrine Hydrochloride.
As of Nov 16, 2026, ANDA 210025 (Phenylephrine Hydrochloride), held by Ph Health, was first approved by FDA on Dec 21, 2018, with 2 approved supplements and 0 published complete response letters.
Phenylephrine Hydrochloride Injection is indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 21, 2018 | Original application | Approved | None posted |
| Phenylephrine Hydrochloride10MG/ML (10MG/ML) · solution;intravenous | Phenylephrine Hydrochloride | Discontinued |
| Phenylephrine Hydrochloride50MG/5ML (10MG/ML) · solution;intravenous | Phenylephrine Hydrochloride | Rx |
| Phenylephrine Hydrochloride100MG/10ML (10MG/ML) · solution;intravenous | Phenylephrine Hydrochloride | Rx |
| Oct 15, 2020 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jul 27, 2020 | Supplement 3Labeling · Standard review | Approved | None posted |
| Dec 21, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters